Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Author: Avi Kapoor | July 29, 2024 05:26am
Shares of Pitney Bowes Inc. (NYSE:PBI) shares rose sharply in today's pre-market trading following a report indicating that the company has sold a part of its e-commerce business to Stord.
Pitney Bowes shares jumped 12.5% to $7.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
- Cognition Therapeutics, Inc. (NASDAQ:CGTX) gained 46% to $3.45 in pre-market trading after the company announced that it will host an investor presentation to discuss results from its phase 2 SHINE study of CT1812 on Monday July 29, 2024.
- Longeveron Inc. (NASDAQ:LGVN) shares climbed 36.3% to $4.69 in pre-market trading after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer’s disease.
- Planet Image International Limited (NASDAQ:YIBO) rose 35.7% to $3.99 in pre-market trading after jumping around 56% on Friday.
- DDC Enterprise Limited (NYSE:DDC) shares gained 22.7% to $0.76 in pre-market trading after gaining 6% on Friday.
- BurgerFi International, Inc. (NASDAQ:BFI) gained 22.1% to $0.5133 in pre-market trading. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.
- Tivic Health Systems, Inc. (NASDAQ:TIVC) shares gained 19.4% to $0.5395 in pre-market trading after gaining 11% on Friday.
- Ambipar Emergency Response (NYSE:AMBI) gained 15.5% to $5.34 in pre-market trading after jumping 29% on Friday.
- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares gained 14.1% to $0.3371 in pre-market trading. TransCode Therapeutics 13G filing showed 3i, LP reported a 9.9% stake in the company, as of July 23.
- Anavex Life Sciences Corp. (NASDAQ:AVXL) gained 11.4% to $7.51 in pre-market trading. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer’s disease.
Losers
- vTv Therapeutics Inc. (NASDAQ:VTVT) shares fell 37.4% to $13.28 in pre-market trading after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.
- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares declined 34% to $0.1690 in pre-market trading after gaining 6% on Friday.
- LuxUrban Hotels Inc. (NASDAQ:LUXH) shares fell 22.1% to $0.1488 in pre-market trading after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.
- Treasure Global Inc. (NASDAQ:TGL) shares fell 19.6% to $1.48 in pre-market trading.
- Globavend Holdings Limited (NASDAQ:GVH) shares declined 13.1% to $0.63 in pre-market trading after surging 24% on Friday.
- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) fell 12.6% to $3.53 in pre-market trading. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.
- INVO Bioscience, Inc. (NASDAQ:INVO) shares fell 11.6% to $0.7250 in pre-market trading after jumping 11% on Friday.
- NuZee Inc (NASDAQ:NUZE) fell 9.7% to $3.40 in pre-market trading after surging around 25% on Friday.
- EZCORP, Inc. (NASDAQ:EZPW) shares dipped 8.8% to $9.41 in pre-market trading.
- Abbott Laboratories (NYSE:ABT) shares fell 6.6% to $98.29 in pre-market trading. A jury ordered Abbott to pay $495 million in compensation and damages in a baby-formula verdict, the Wall Street Journal reported.
Now Read This:
Posted In: ABT AMBI AVXL BFI CERO CGTX DDC EZPW GVH INVO LGVN LUXH NUZE PBI PHIO RNAZ TGL TIVC VTVT YIBO
